Dissecting the molecular mechanisms of neurodegenerative diseases through network biology

Frontiers in Aging Neuroscience

Volumn 9, Issue MAY, 2017, Pages

  Santiago, Jose A ^a   Bottero, Virginie ^a   Potashkin, Judith A ^a  

^a ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Alzheimer's disease; Huntington's disease; Molecular mechanisms; Network biology; Parkinson's disease

Indexed keywords

BIOLOGICAL MARKER;

AGING; ALZHEIMER DISEASE; EPIGENETICS; HUMAN; HUNTINGTON CHOREA; MOLECULAR PATHOLOGY; NERVE CELL NETWORK; NONHUMAN; PARKINSON DISEASE; PERSONALIZED MEDICINE; REVIEW;

EID: 85020035589     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2017.00166     Document Type: Review

References (106)

1. Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., and Svenningsson, P. (2012). Depression in Parkinson disease-epidemiology, mechanisms and management. Nat. Rev. Neurol. 8, 35-47. doi: 10.1038/nrneurol.2011.189
2. Acquaah-Mensah, G. K., Agu, N., Khan, T., and Gardner, A. (2015). A regulatory role for the insulin- and BDNF-linked RORA in the hippocampus: implications for Alzheimer's disease. J. Alzheimers Dis. 44, 827-838. doi: 10.3233/JAD-141731
3. An, M. C., Zhang, N., Scott, G., Montoro, D., Wittkop, T., Mooney, S., et al. (2012). Genetic correction of Huntington's disease phenotypes in induced pluripotent stem cells. Cell Stem Cell 11, 253-263. doi: 10.1016/j.stem.2012.04.026
4. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Ell, P., Soderlund, T., et al. (2013). Exenatide and the treatment of patients with Parkinson's disease. J. Clin. Invest. 123, 2730-2736. doi: 10.1172/JCI68295
5. Aviles-Olmos, I., Dickson, J., Kefalopoulou, Z., Djamshidian, A., Kahan, J., Ell, P., et al. (2014). Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J. Parkinsons Dis. 4, 337-344. doi: 10.3233/JPD-140364
6. Bamidis, P. D., Vivas, A. B., Styliadis, C., Frantzidis, C., Klados, M., Schlee, W., et al. (2014). A review of physical and cognitive interventions in aging. Neurosci. Biobehav. Rev. 44, 206-220. doi: 10.1016/j.neubiorev.2014.03.019
7. Benayoun, B. A., Pollina, E. A., and Brunet, A. (2015). Epigenetic regulation of ageing: linking environmental inputs to genomic stability. Nat. Rev. Mol. Cell Biol. 16, 593-610. doi: 10.1038/nrm4048
8. Borrell-Pagès, M., Zala, D., Humbert, S., and Saudou, F. (2006). Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci. 63, 2642-2660. doi: 10.1007/s00018-006-6242-0
9. Brehme, M., Voisine, C., Rolland, T., Wachi, S., Soper, J. H., Zhu, Y., et al. (2014). A chaperome subnetwork safeguards proteostasis in aging and neurodegenerative disease. Cell Rep. 9, 1135-1150. doi: 10.1016/j.celrep.2014.09.042
10. Brundin, P., and Wyse, R. (2015). Parkinson disease: laying the foundations for disease-modifying therapies in PD. Nat. Rev. Neurol. 11, 553-555. doi: 10.1038/nrneurol.2015.150
11. Brunet, A., and Berger, S. L. (2014). Epigenetics of aging and aging-related disease. J. Gerontol. A Biol. Sci. Med. Sci. 69, S17-S20. doi: 10.1093/gerona/glu042
12. Calderone, A., Formenti, M., Aprea, F., Papa, M., Alberghina, L., Colangelo, A. M., et al. (2016). Comparing Alzheimer's and Parkinson's diseases networks using graph communities structure. BMC Syst. Biol. 10:25. doi: 10.1186/s12918-016-0270-7
13. Carta, A. R., and Simuni, T. (2015). Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease. Expert Opin. Investig. Drugs 24, 219-227. doi: 10.1517/13543784.2015.963195
14. Chen, Y., Zhu, J., Lum, P. Y., Yang, X., Pinto, S., MacNeil, D. J., et al. (2008). Variations in DNA elucidate molecular networks that cause disease. Nature 452, 429-435. doi: 10.1038/nature06757
15. Ciryam, P., Kundra, R., Freer, R., Morimoto, R. I., Dobson, C. M., and Vendruscolo, M. (2016). A transcriptional signature of Alzheimer's disease is associated with a metastable subproteome at risk for aggregation. Proc. Natl. Acad. Sci. U S A 113, 4753-4758. doi: 10.1073/pnas.1516604113
16. Coetzee, S. G., Pierce, S., Brundin, P., Brundin, L., Hazelett, D. J., and Coetzee, G. A. (2016). Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology. Sci. Rep. 6:30509. doi: 10.1038/srep30509
17. Coon, K. D., Myers, A. J., Craig, D. W., Webster, J. A., Pearson, J. V., Lince, D. H., et al. (2007). A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J. Clin. Psychiatry 68, 613-618. doi: 10.4088/jcp.v68n0419
18. Corradini, B. R., Iamashita, P., Tampellini, E., Farfel, J. M., Grinberg, L. T., and Moreira-Filho, C. A. (2014). Complex network-driven view of genomic mechanisms underlying Parkinson's disease: analyses in dorsal motor vagal nucleus, locus coeruleus and substantia nigra. Biomed Res. Int. 2014:543673. doi: 10.1155/2014/543673
19. De Strooper, B., and Karran, E. (2016). The cellular phase of Alzheimer's disease. Cell 164, 603-615. doi: 10.1016/j.cell.2015.12.056
20. Desikan, R. S., Schork, A. J., Wang, Y., Witoelar, A., Sharma, M., McEvoy, L. K., et al. (2015). Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. Mol. Psychiatry 20, 1588-1595. doi: 10.1038/mp.2015.6
21. Donmez, G., and Outeiro, T. F. (2013). SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol. Med. 5, 344-352. doi: 10.1002/emmm.201302451
22. Duff, K., Paulsen, J. S., Beglinger, L. J., Langbehn, D. R., Stout, J. C., and Predict-HD Investigators of the Huntington Study Group. (2007). Psychiatric symptoms in Huntington's disease before diagnosis: the predict-HD study. Biol. Psychiatry 62, 1341-1346. doi: 10.1016/j.biopsych.2006.11.034
23. Dusonchet, J., Li, H., Guillily, M., Liu, M., Stafa, K., Derada Troletti, C., et al. (2014). A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. Hum. Mol. Genet. 23, 4887-4905. doi: 10.1093/hmg/ddu202
24. Ehrlich, M. E. (2012). Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics 9, 270-284. doi: 10.1007/s13311-012-0112-2
25. Fernández-Santiago, R., Carballo-Carbajal, I., Castellano, G., Torrent, R., Richaud, Y., Sánchez-Danés, A., et al. (2015). Aberrant epigenome in iPSC-derived dopaminergic neurons from Parkinson's disease patients. EMBO Mol. Med. 7, 1529-1546. doi: 10.15252/emmm.201505439
26. Fischer, A. (2014). Targeting histone-modifications in Alzheimer's disease. What is the evidence that this is a promising therapeutic avenue? Neuropharmacology 80, 95-102. doi: 10.1016/j.neuropharm.2014.01.038
27. Gao, L., Zhao, G., Fang, J. S., Yuan, T. Y., Liu, A. L., and Du, G. H. (2014). Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential anti-Parkinson agents. FEBS J. 281, 1110-1122. doi: 10.1111/febs.12672
28. Glaab, E., and Schneider, R. (2015). Comparative pathway and network analysis of brain transcriptome changes during adult aging and in Parkinson's disease. Neurobiol. Dis. 74, 1-13. doi: 10.1016/j.nbd.2014.11.002
29. Goate, A., Chartier-Harlin, M. C., Mullan, M., Brown, J., Crawford, F., Fidani, L., et al. (1991). Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704-706. doi: 10.1038/349704a0
30. Goh, K. I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., and Barabási, A. L. (2007). The human disease network. Proc. Natl. Acad. Sci. U S A 104, 8685-8690. doi: 10.1073/pnas.0701361104
31. Grove, V. E. Jr., Quintanilla, J., and DeVaney, G. T. (2000). Improvement of Huntington's disease with olanzapine and valproate. N. Engl. J. Med. 343, 973-974. doi: 10.1056/NEJM200009283431316
32. Hallock, P., and Thomas, M. A. (2012). Integrating the Alzheimer's disease proteome and transcriptome: a comprehensive network model of a complex disease. OMICS 16, 37-49. doi: 10.1089/omi.2011.0054
33. Hamilton, R. L. (2000). Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using a-synuclein immunohistochemistry. Brain Pathol. 10, 378-384. doi: 10.1111/j.1750-3639.2000.tb00269.x
34. Herskovits, A. Z., and Guarente, L. (2013). Sirtuin deacetylases in neurodegenerative diseases of aging. Cell Res. 23, 746-758. doi: 10.1038/cr.2013.70
35. Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome Biol. 14:R115. doi: 10.1186/gb-2013-14-10-r115
36. Horvath, S., Langfelder, P., Kwak, S., Aaronson, J., Rosinski, J., Vogt, T. F., et al. (2016). Huntington's disease accelerates epigenetic aging of human brain and disrupts DNA methylation levels. Aging 8, 1485-1512. doi: 10.18632/aging.101005
37. Humphries, C. E., Kohli, M. A., Nathanson, L., Whitehead, P., Beecham, G., Martin, E., et al. (2015). Integrated whole transcriptome and DNA methylation analysis identifies gene networks specific to late-onset Alzheimer's disease. J. Alzheimers Dis. 44, 977-987. doi: 10.3233/JAD-141989
38. Ibáñez, K., Boullosa, C., Tabarés-Seisdedos, R., Baudot, A., and Valencia, A. (2014). Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses. PLoS Genet. 10:e1004173. doi: 10.1371/journal.pgen.1004173
39. Jack, C. R. Jr., Wiste, H. J., Weigand, S. D., Knopman, D. S., Vemuri, P., Mielke, M. M., et al. (2015). Age, sex, and APOE e4 effects on memory, brain structure, and ß-amyloid across the adult life span. JAMA Neurol. 72, 511-519. doi: 10.1001/jamaneurol.2014.4821
40. Janssen, J. C., Beck, J. A., Campbell, T. A., Dickinson, A., Fox, N. C., Harvey, R. J., et al. (2003). Early onset familial Alzheimer's disease: mutation frequency in 31 families. Neurology 60, 235-239. doi: 10.1212/01.WNL.0000042088.22694.e3
41. Jiang, P., Scarpa, J. R., Fitzpatrick, K., Losic, B., Gao, V. D., Hao, K., et al. (2015). A systems approach identifies networks and genes linking sleep and stress: implications for neuropsychiatric disorders. Cell Rep. 11, 835-848. doi: 10.1016/j.celrep.2015.04.003
42. Jiang, S., Tang, L., Zhao, N., Yang, W., Qiu, Y., and Chen, H. Z. (2016). A systems view of the differences between APOE e4 carriers and non-carriers in Alzheimer's disease. Front. Aging Neurosci. 8:171. doi: 10.3389/fnagi.2016.00171
43. Kandimalla, R. J., Prabhakar, S., Binukumar, B. K., Wani, W. Y., Gupta, N., Sharma, D. R., et al. (2011). Apo-Ee4 allele in conjunction with Aß42 and tau in CSF: biomarker for Alzheimer's disease. Curr. Alzheimer Res. 8, 187-196. doi: 10.2174/156720511795256071
44. Keane, H., Ryan, B. J., Jackson, B., Whitmore, A., and Wade-Martins, R. (2015). Protein-protein interaction networks identify targets which rescue the MPP+ cellular model of Parkinson's disease. Sci. Rep. 5:17004. doi: 10.1038/srep17004
45. Khanam Irin, A., Kodamullil, A. T., Gündel, M., and Hofmann-Apitius, M. (2015). Computational modelling approaches on epigenetic factors in neurodegenerative and autoimmune diseases and their mechanistic analysis. J. Immunol. Res. 2015:737168. doi: 10.1155/2015/737168
46. Kikuchi, M., Ogishima, S., Miyamoto, T., Miyashita, A., Kuwano, R., Nakaya, J., et al. (2013). Identification of unstable network modules reveals disease modules associated with the progression of Alzheimer's disease. PLoS One 8:e76162. doi: 10.1371/journal.pone.0076162
47. Kim, Y. H., Beak, S. H., Charidimou, A., and Song, M. (2016). Discovering new genes in the pathways of common sporadic neurodegenerative diseases: a bioinformatics approach. J. Alzheimers Dis. 51, 293-312. doi: 10.3233/JAD-150769
48. Kim, S., Seo, J. H., and Suh, Y. H. (2004). a-synuclein, Parkinson's disease, and Alzheimer's disease. Parkinsonism Relat. Disord. 10, S9-S13. doi: 10.1016/j.parkreldis.2003.11.005
49. Kraft, E. (2012). Cognitive function, physical activity, and aging: possible biological links and implications for multimodal interventions. Neuropsychol. Dev. Cogn. B Aging Neuropsychol. Cogn. 19, 248-263. doi: 10.1080/13825585.2011.645010
50. Langfelder, P., Cantle, J. P., Chatzopoulou, D., Wang, N., Gao, F., Al-Ramahi, I., et al. (2016). Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice. Nat. Neurosci. 19, 623-633. doi: 10.1038/nn.4256
51. Langfelder, P., and Horvath, S. (2008). WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9:559. doi: 10.1186/1471-2105-9-559
52. Levine, M. E., Lu, A. T., Bennett, D. A., and Horvath, S. (2015). Epigenetic age of the pre-frontal cortex is associated with neuritic plaques, amyloid load, and Alzheimer's disease related cognitive functioning. Aging 7, 1198-1211. doi: 10.18632/aging.100864
53. Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., et al. (1995). Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977. doi: 10.1126/science.7638622
54. Liang, D., Han, G., Feng, X., Sun, J., Duan, Y., and Lei, H. (2012). Concerted perturbation observed in a hub network in Alzheimer's disease. PLoS One 7:e40498. doi: 10.1371/journal.pone.0040498
55. Liang, M. H., Wendland, J. R., and Chuang, D. M. (2008). Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling. Mol. Cell. Neurosci. 37, 440-453. doi: 10.1016/j.mcn.2007.10.017
56. Lin, M. K., and Farrer, M. J. (2014). Genetics and genomics of Parkinson's disease. Genome Med. 6:48. doi: 10.1186/gm566
57. Linghu, B., Snitkin, E. S., Hu, Z., Xia, Y., and Delisi, C. (2009). Genome-wide prioritization of disease genes and identification of disease-disease associations from an integrated human functional linkage network. Genome Biol. 10:R91. doi: 10.1186/gb-2009-10-9-r91
58. Liu, G., Bao, X., Jiang, Y., Liao, M., Jiang, Q., Feng, R., et al. (2015). Identifying the association between Alzheimer's disease and Parkinson's disease using genome-wide association studies and protein-protein interaction network. Mol. Neurobiol. 52, 1629-1636. doi: 10.1007/s12035-014-8946-8
59. MacDonald, M. E., Ambrose, C. M., Duyao, M. P., Myers, R. H., Lin, C., Srinidhi, L., et al. (1993). A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72, 971-983. doi: 10.1016/0092-8674(93)90585-e
60. Marra, C., Bizzarro, A., Daniele, A., De Luca, L., Ferraccioli, M., Valenza, A., et al. (2004). Apolipoprotein E e4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients. Dement. Geriatr. Cogn. Disord. 18, 125-131. doi: 10.1159/000079191
61. Meng, Q., Ying, Z., Noble, E., Zhao, Y., Agrawal, R., Mikhail, A., et al. (2016). Systems nutrigenomics reveals brain gene networks linking metabolic and brain disorders. EBioMedicine 7, 157-166. doi: 10.1016/j.ebiom.2016.04.008
62. Mercado, G., Valdés, P., and Hetz, C. (2013). An ERcentric view of Parkinson's disease. Trends Mol. Med. 19, 165-175. doi: 10.1016/j.molmed.2012.12.005
63. Miller, J. A., Oldham, M. C., and Geschwind, D. H. (2008). A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging. J. Neurosci. 28, 1410-1420. doi: 10.1523/JNEUROSCI.4098-07.2008
64. Miller, J. A., Woltjer, R. L., Goodenbour, J. M., Horvath, S., and Geschwind, D. H. (2013). Genes and pathways underlying regional and cell type changes in Alzheimer's disease. Genome Med. 5:48. doi: 10.1186/gm452
65. Mina, E., van Roon-Mom, W., Hettne, K., van Zwet, E., Goeman, J., Neri, C., et al. (2016). Common disease signatures from gene expression analysis in Huntington's disease human blood and brain. Orphanet J. Rare Dis. 11:97. doi: 10.1186/s13023-016-0475-2
66. Narayanan, M., Huynh, J. L., Wang, K., Yang, X., Yoo, S., McElwee, J., et al. (2014). Common dysregulation network in the human prefrontal cortex underlies two neurodegenerative diseases. Mol. Syst. Biol. 10:743. doi: 10.15252/msb.20145304
67. Neueder, A., and Bates, G. P. (2014). A common gene expression signature in Huntington's disease patient brain regions. BMC Med. Genomics 7:60. doi: 10.1186/s12920-014-0060-2
68. NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. (2015). Pioglitazone in early Parkinson's disease: a phase 2, multicentre, couble-blind, randomised trial. Lancet Neurol. 14, 795-803. doi: 10.1016/s1474-4422(15)00144-1
69. Nolan, Y. M., Sullivan, A. M., and Toulouse, A. (2013). Parkinson's disease in the nuclear age of neuroinflammation. Trends Mol. Med. 19, 187-196. doi: 10.1016/j.molmed.2012.12.003
70. Orre, M., Kamphuis, W., Osborn, L. M., Jansen, A. H., Kooijman, L., Bossers, K., et al. (2014). Isolation of glia from Alzheimer's mice reveals inflammation and dysfunction. Neurobiol. Aging 35, 2746-2760. doi: 10.1016/j.neurobiolaging.2014.06.004
71. Orr, H. T., and Zoghbi, H. Y. (2007). Trinucleotide repeat disorders. Annu. Rev. Neurosci. 30, 575-621. doi: 10.1146/annurev.neuro.29.051605.113042
72. Ota, M., Yasuno, F., Ito, H., Seki, C., Nozaki, S., Asada, T., et al. (2006). Age-related decline of dopamine synthesis in the living human brain measured by positron emission tomography with L-[ß-11C]DOPA. Life Sci. 79, 730-736. doi: 10.1016/j.lfs.2006.02.017
73. Pike, K. E., Savage, G., Villemagne, V. L., Ng, S., Moss, S. A., Maruff, P., et al. (2007). ß-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 130, 2837-2844. doi: 10.1093/brain/awm238
74. Pristerè, A., Lin, W., Kaufmann, A. K., Brimblecombe, K. R., Threlfell, S., Dodson, P. D., et al. (2015). Transcription factors FOXA1 and FOXA2 maintain dopaminergic neuronal properties and control feeding behavior in adult mice. Proc. Natl. Acad. Sci. U S A 112, E4929-E4938. doi: 10.1073/pnas.1503911112
75. Raja, M., Soleti, F., and Bentivoglio, A. R. (2015). Lithium treatment in patients With Huntington's disease and suicidal behavior. Mov. Disord 30:1438. doi: 10.1002/mds.26260
76. Rhinn, H., Qiang, L., Yamashita, T., Rhee, D., Zolin, A., Vanti, W., et al. (2012). Alternative a-synuclein transcript usage as a convergent mechanism in Parkinson's disease pathology. Nat. Commun. 3:1084. doi: 10.1038/ncomms2032
77. Richard, F., Helbecque, N., Neuman, E., Guez, D., Levy, R., and Amouyel, P. (1997). APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet 349:539. doi: 10.1016/s0140-6736(97)80089-x
78. Ring, K. L., An, M. C., Zhang, N., O'Brien, R. N., Ramos, E. M., Gao, F., et al. (2015). Genomic analysis reveals disruption of striatal neuronal development and therapeutic targets in human Huntington's disease neural stem cells. Stem Cell Reports 5, 1023-1038. doi: 10.1016/j.stemcr.2015.11.005
79. Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., et al. (2014). Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat. Rev. Neurol. 10, 204-216. doi: 10.1038/nrneurol.2014.24
80. Santiago, J. A., Littlefield, A. M., and Potashkin, J. A. (2016). Integrative transcriptomic meta-analysis of Parkinson's disease and depression identifies NAMPT as a potential blood biomarker for de novo Parkinson's disease. Sci. Rep. 6:34579. doi: 10.1038/srep34579
81. Santiago, J. A., and Potashkin, J. A. (2013a). Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes. PLoS One 8:e83940. doi: 10.1371/journal.pone.0083940
82. Santiago, J. A., and Potashkin, J. A. (2013b). Shared dysregulated pathways lead to Parkinson's disease and diabetes. Trends Mol. Med. 19, 176-186. doi: 10.1016/j.molmed.2013.01.002
83. Santiago, J. A., and Potashkin, J. A. (2014a). A network approach to clinical intervention in neurodegenerative diseases. Trends Mol. Med. 20, 694-703. doi: 10.1016/j.molmed.2014.10.002
84. Santiago, J. A., and Potashkin, J. A. (2014b). A network approach to diagnostic biomarkers in progressive supranuclear palsy. Mov. Disord. 29, 550-555. doi: 10.1002/mds.25761
85. Santiago, J. A., and Potashkin, J. A. (2014c). System-based approaches to decode the molecular links in Parkinson's disease and diabetes. Neurobiol. Dis. 72, 84-91. doi: 10.1016/j.nbd.2014.03.019
86. Santiago, J. A., and Potashkin, J. A. (2015). Network-based metaanalysis identifies HNF4A and PTBP1 as longitudinally dynamic biomarkers for Parkinson's disease. Proc. Natl. Acad. Sci. U S A 112, 2257-2262. doi: 10.1073/pnas.1423573112
87. Santiago, J. A., Scherzer, C. R., and Potashkin, J. A. (2014). Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. PLoS One 9:e109042. doi: 10.1371/journal.pone.0109042
88. Satake, W., Nakabayashi, Y., Mizuta, I., Hirota, Y., Ito, C., Kubo, M., et al. (2009). Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease. Nat. Genet. 41, 1303-1307. doi: 10.1038/ng.485
89. Scarpa, J. R., Jiang, P., Losic, B., Readhead, B., Gao, V. D., Dudley, J. T., et al. (2016). Systems genetic analyses highlight a TGFß-FOXO3 dependent striatal astrocyte network conserved across species and associated with stress, sleep, and Huntington's disease. PLoS Genet. 12:e1006137. doi: 10.1371/journal.pgen.1006137
90. Scheuing, L., Chiu, C. T., Liao, H. M., Linares, G. R., and Chuang, D. M. (2014). Preclinical and clinical investigations of mood stabilizers for Huntington's disease: what have we learned? Int. J. Biol. Sci. 10, 1024-1038. doi: 10.7150/ijbs.9898
91. Schneider, A., Rajendran, L., Honsho, M., Gralle, M., Donnert, G., Wouters, F., et al. (2008). Flotillin-dependent clustering of the amyloid precursor protein regulates its endocytosis and amyloidogenic processing in neurons. J. Neurosci. 28, 2874-2882. doi: 10.1523/JNEUROSCI.5345-07.2008
92. Seidl, S. E., Santiago, J. A., Bilyk, H., and Potashkin, J. A. (2014). The emerging role of nutrition in Parkinson's disease. Front. Aging Neurosci. 6:36. doi: 10.3389/fnagi.2014.00036
93. Simon, D. K., Simuni, T., Elm, J., Clark-Matott, J., Graebner, A. K., Baker, L., et al. (2015). Peripheral biomarkers of Parkinson's disease progression and pioglitazone effects. J. Parkinsons Dis. 5, 731-736. doi: 10.3233/JPD-150666
94. Simón-Sánchez, J., Schulte, C., Bras, J. M., Sharma, M., Gibbs, J. R., Berg, D., et al. (2009). Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 41, 1308-1312. doi: 10.1038/ng.487
95. Solt, L. A., and Burris, T. P. (2012). Action of RORs and their ligands in (patho)physiology. Trends Endocrinol. Metab. 23, 619-627. doi: 10.1016/j.tem.2012.05.012
96. Talwar, P., Silla, Y., Grover, S., Gupta, M., Agarwal, R., Kushwaha, S., et al. (2014). Genomic convergence and network analysis approach to identify candidate genes in Alzheimer's disease. BMC Genomics 15:199. doi: 10.1186/1471-2164-15-199
97. Taylor, I. W., Linding, R., Warde-Farley, D., Liu, Y., Pesquita, C., Faria, D., et al. (2009). Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat. Biotechnol. 27, 199-204. doi: 10.1038/nbt.1522
98. Turner, A. P., Lones, M. A., Fuente, L. A., Stepney, S., Caves, L. S., and Tyrrell, A. M. (2013). The incorporation of epigenetics in artificial gene regulatory networks. Biosystems 112, 56-62. doi: 10.1016/j.biosystems.2013.03.013
99. Wang, L. Y., Wang, P., Li, M. J., Qin, J., Wang, X., Zhang, M. Q., et al. (2011). EpiRegNet: constructing epigenetic regulatory network from high throughput gene expression data for humans. Epigenetics 6, 1505-1512. doi: 10.4161/epi.6.12.18176
100. Watanabe, T., Tajima, H., Hironori, H., Nakagawara, H., Ohnishi, I., Takamura, H., et al. (2011). Sodium valproate blocks the transforming growth factor (TGF)-ß1 autocrine loop and attenuates the TGF-ß1-induced collagen synthesis in a human hepatic stellate cell line. Int. J. Mol. Med. 28, 919-925. doi: 10.3892/ijmm.2011.768
101. Wilkaniec, A., Czapski, G. A., and Adamczyk, A. (2016). Cdk5 at crossroads of protein oligomerization in neurodegenerative diseases: facts and hypotheses. J. Neurochem. 136, 222-233. doi: 10.1111/jnc.13365
102. Wilson, V. L., Smith, R. A., Ma, S., and Cutler, R. G. (1987). Genomic 5-methyldeoxycytidine decreases with age. J. Biol. Chem. 262, 9948-9951.
103. Xie, A., Gao, J., Xu, L., and Meng, D. (2014). Shared mechanisms of neurodegeneration in Alzheimer's disease and Parkinson's disease. Biomed Res. Int. 2014:648740. doi: 10.1155/2014/648740
104. Zampieri, M., Ciccarone, F., Calabrese, R., Franceschi, C., Bürkle, A., and Caiafa, P. (2015). Reconfiguration of DNA methylation in aging. Mech. Ageing Dev. 151, 60-70. doi: 10.1016/j.mad.2015.02.002
105. Zhang, B., Gaiteri, C., Bodea, L. G., Wang, Z., McElwee, J., Podtelezhnikov, A. A., et al. (2013). Integrated systems approach identifies genetic nodes and networks in late-onset Alzheimer's disease. Cell 153, 707-720. doi: 10.1016/j.cell.2013.03.030
106. Zou, X. D., Guo, S. Q., Hu, Z. W., and Li, W. L. (2016). NAMPT protects against 6-hydroxydopamine-induced neurotoxicity in PC12 cells through modulating SIRT1 activity. Mol. Med. Rep. 13, 4058-4064. doi: 10.3892/mmr.2016.5034